Rivaroxaban News and Research

RSS

Modern blood thinners linked to reduced risk of bleeding

Modern blood-thinning drugs (known as NOACs) reduce the risk of serious bleeding by up to 45 percent compared to the traditional drug Waran in the treatment of blood clots in the legs and lungs.

29 Aug 2023

Do system-level DOAC therapy management services affect anticoagulation outcomes for AF patients compared to usual care?

Researchers compared outcomes related to three direct oral anticoagulant (DOAC) care models.

10 Jul 2023

Research offers a cost-effectiveness analysis of anticoagulant drugs for cancer-associated thrombosis

Newly published research out of the University of Cincinnati and the University of California-Davis shows that direct oral anticoagulant (DOAC) drugs are more effective and are more cost-effective than low molecular weight heparin for treating cancer-associated thrombosis.

4 Jan 2023

Cost-effectiveness analysis of four interventions for treatment of cancer-associated thrombosis

A cost-effectiveness analysis comparing direct oral anticoagulants (DOACs) to low-molecular-weight heparin (LMWH) found that DOACs are both more medically effective and cost-effective than LMWH when treating cancer-associated thrombosis (CAT).

27 Dec 2022

Direct oral anticoagulants more effective and cost-effective for treating cancer-associated thrombosis

Research conducted by UC Davis Comprehensive Cancer Center and the University of Cincinnati shows that direct oral anti-coagulant (DOAC) drugs are more effective and are more cost-effective than low molecular weight heparin (LMWH) for treating cancer-associated thrombosis (CAT).

27 Dec 2022

Does nirmatrelvir and ritonavir reduce the risk of hospitalization or death among outpatients with early COVID-19?

Researchers investigated the efficacy of ritonavir and nirmatrelvir combination treatment in reducing the risk of COVID-19 severity outcomes such as hospital admissions and deaths when administered during the initial period of SARS-CoV-2 infections.

16 Dec 2022

No benefit of low dose apixaban following acute COVID-19

The HEAL-COVID trial compared the efficacy of Apixaban to standard care in adults who have recently recovered from severe COVID-19.

14 Dec 2022

Additional six weeks of anti-clotting treatment reduces further clot risk after distal DVT

Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six after a blood clot in the lower leg reduces the risk of further clots developing up to two years after treatment, finds a trial published by The BMJ today.

24 Nov 2022

Study explores the effect of COVID-19 on platelet function

A new study posted in the pre-print server bioRxiv* aimed to analyze the impact of COVID-19 on platelet proteome and relate the functional responses of platelets and the formation of platelet-neutrophil aggregate in hospitalized COVID-19 patients.

17 Oct 2022

SARS-CoV-2 infection may be a trigger of myelin oligodendrocyte glycoprotein-associated disorder

A new study reported four cases of Myelin Oligodendrocyte Glycoprotein-Associated Disorder that commenced after SARS-CoV-2 infection.

21 Jun 2022

Low-dose apixaban treatment reduces recurrence of venous thromboembolism compared to anticoagulant discontinuation after negative D-dimer

Patients who have suffered from a first episode of unprovoked venous thromboembolism (VTE) have an eight times higher risk of recurrence if they stop treatment after repeated negative D-dimer tests, instead of continuing with low-dose anticoagulant (apixaban).

20 May 2022

Many treatments for intracerebral hemorrhage are not as effective as previously thought, guideline suggests

Some treatments or preventive therapies used to manage intracerebral hemorrhages (ICH), or a bleeding stroke, are not as effective as previously believed, according to the new American Heart Association/American Stroke Association guideline for caring for people with spontaneous ICH, published today in the Association's Stroke journal.

17 May 2022

Reduced kidney function caused by antithrombotic therapy can influence bleeding events

Antithrombotic therapy is prescribed to prevent thrombotic (blood clotting inside a blood vessel) events but the treatment also increases the likelihood of experiencing a bleeding event, which can be extremely serious if it occurs in a vital organ.

25 Mar 2022

Meta-analysis finds intensified anticoagulation had no effect on short term mortality among hospitalized COVID-19 patients

A recent systematic review and meta-analysis evaluated the safety and efficacy of intensified anticoagulation therapy in COVID-19 patients.

11 Mar 2022

Impact of atrial fibrillation in COVID-19 vaccine-induced pericarditis patients

In a new study, a team of researchers described the case of a healthy 49-year old male patient with new-onset atrial fibrillation after receiving the second dose of the COVID-19 mRNA-1273 (Moderna) vaccine.

19 Jan 2022

Trial tests effectiveness of two prospective stroke therapies over standard of care

Another goal of the study is to screen all participants for a mutation known to prevent clopidogrel, a prodrug, from being fully metabolized into its active form.

2 Sep 2021

Study elucidates the use of anticoagulants to treat bleeding in patients with gastrointestinal cancers

A study by Mayo Clinic researchers provides some clarity in the use of direct oral anticoagulants (DOAC), such as apixaban and rivaroxaban, to treat acute venous thromboembolism (VTE) in patients with gastrointestinal cancers.

5 Jun 2021

Rivaroxaban reduces the occurrence of severe ischemic events in patients with peripheral artery disease

Rivaroxaban, in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients with symptomatic peripheral artery disease (PAD) who underwent lower extremity revascularization, a procedure to open blocked arteries in the leg.

17 May 2021

Study shows adverse outcomes associated with use of more blood thinners

More blood thinners aren't automatically better, another study confirms. A new publication in JAMA Internal Medicine focuses on the minimal pros and the concerning cons of combining a daily aspirin with a drug from the newer class of anticoagulants that include apixaban, dabigatran, edoxaban and rivaroxaban.

19 Apr 2021

Dual-pathway approach can lead to better outcomes in patients with heart stents

Pairing a blood-thinning drug with aspirin daily for patients who have an angioplasty with a stent can contribute to better health outcomes, including lower risk of death, than aspirin alone, according to a recent study by cardiologists at the University of Alberta and Mazankowski Alberta Heart Institute.

28 May 2020